Zhou Yingying, Zhou Weibing, Liu Qiong, Fan Zhiru, Yang Zhen, Tu Qingsong, Li Li, Liu Haifeng
Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410000, China.
Tumour Biol. 2014 Jan;35(1):21-5. doi: 10.1007/s13277-013-0990-x. Epub 2013 Dec 3.
Radiotherapy is an important weapon in the treatment of breast cancer, but normal tissue injury after radiotherapy can be a threat for patients. Genetic markers conferring the ability to identify hyper-sensitive patients at risk of normal tissue injury in advance would considerably improve therapy. Association studies on genetic variation and occurrence of normal tissue injury can help us identify such markers, but previous studies on the association between XRCC1 R399Q polymorphism and risk of normal tissue injury after radiotherapy in breast cancer patients report conflicting findings. We performed a meta-analysis to comprehensively evaluate the association between XRCC1 R399Q polymorphism and risk of normal tissue injury after radiotherapy in breast cancer patients. The pooled odds ratios (ORs) with their 95% confidence interval (95% CIs) were calculated to assess the strength of the association. Fourteen case-control studies with a total of 2,448 breast cancer cases were finally included into the meta-analysis. Overall, XRCC1 R399Q polymorphism was significantly associated with increased risk of normal tissue injury after radiotherapy under all three models (for QQ versus RR: fixed-effects OR = 1.06, 95% CI 1.00-1.13, P = 0.050; for RQ versus RR: fixed-effects OR = 1.05, 95% CI 1.00-1.10, P = 0.047; for QQ/RQ versus RR: fixed-effects OR = 1.26, 95% CI 1.01-1.58, P = 0.041). The meta-analysis suggests that XRCC1 R399Q polymorphism was significantly associated with increased risk of normal tissue injury after radiotherapy in breast cancer patients, and XRCC1 R399Q polymorphism is a genetic marker of normal tissue injury after radiotherapy in breast cancer patients.
放射治疗是乳腺癌治疗中的一项重要手段，但放疗后正常组织损伤可能对患者构成威胁。能够提前识别有正常组织损伤风险的超敏患者的基因标志物将显著改善治疗效果。关于基因变异与正常组织损伤发生情况的关联研究有助于我们识别此类标志物，但先前关于乳腺癌患者放疗后XRCC1基因R399Q多态性与正常组织损伤风险之间关联的研究结果相互矛盾。我们进行了一项荟萃分析，以全面评估乳腺癌患者放疗后XRCC1基因R399Q多态性与正常组织损伤风险之间的关联。计算合并比值比（OR）及其95%置信区间（95%CI）以评估关联强度。最终，共有2448例乳腺癌病例的14项病例对照研究被纳入荟萃分析。总体而言，在所有三种模型下，XRCC1基因R399Q多态性均与放疗后正常组织损伤风险增加显著相关（QQ与RR相比：固定效应OR = 1.06，95%CI 1.00 - 1.13，P = 0.050；RQ与RR相比：固定效应OR = 1.05，95%CI 1.00 - 1.10，P = 0.047；QQ/RQ与RR相比：固定效应OR = 1.26，95%CI 1.01 - 1.58，P = 0.041）。荟萃分析表明，XRCC1基因R399Q多态性与乳腺癌患者放疗后正常组织损伤风险增加显著相关，且XRCC1基因R399Q多态性是乳腺癌患者放疗后正常组织损伤的一个基因标志物。
